Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_2
6
100%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

unknown117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

NCT04447469
completedphase_2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04492514
completedphase_2

KPL-301 for Subjects With Giant Cell Arteritis

NCT03827018
completedphase_2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04463004
completedphase_2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04399980
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04447469Phase 2

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Completed
NCT04492514Phase 2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed
NCT03827018Phase 2

KPL-301 for Subjects With Giant Cell Arteritis

Completed
NCT04463004Phase 2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed
NCT04399980Phase 2

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed
NCT04397497Phase 2

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6